ONCOGENEX PHARMACEUTICALS IN's ticker is OGXI and the CUSIP is 68230A106. A total of 57 filers reported holding ONCOGENEX PHARMACEUTICALS IN in Q1 2015. The put-call ratio across all filers is - and the average weighting 0.0%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q2 2017 | $5,000 | +150.0% | 15,154 | +195.1% | 0.00% | – |
| Q1 2017 | $2,000 | -33.3% | 5,135 | -7.1% | 0.00% | – |
| Q4 2016 | $3,000 | 0.0% | 5,525 | -6.8% | 0.00% | – |
| Q3 2016 | $3,000 | -40.0% | 5,925 | +3.5% | 0.00% | – |
| Q2 2016 | $5,000 | +150.0% | 5,725 | +97.4% | 0.00% | – |
| Q1 2016 | $2,000 | -50.0% | 2,900 | 0.0% | 0.00% | – |
| Q4 2015 | $4,000 | -85.2% | 2,900 | -76.4% | 0.00% | – |
| Q3 2015 | $27,000 | -60.9% | 12,270 | -58.7% | 0.00% | – |
| Q2 2015 | $69,000 | +7.8% | 29,740 | -0.3% | 0.00% | – |
| Q1 2015 | $64,000 | +326.7% | 29,840 | +335.6% | 0.00% | – |
| Q4 2014 | $15,000 | -28.6% | 6,850 | -8.0% | 0.00% | – |
| Q3 2014 | $21,000 | -34.4% | 7,448 | -12.9% | 0.00% | – |
| Q2 2014 | $32,000 | -95.1% | 8,550 | -84.5% | 0.00% | – |
| Q1 2014 | $649,000 | +19.3% | 55,225 | -15.5% | 0.00% | – |
| Q4 2013 | $544,000 | -23.7% | 65,335 | -15.1% | 0.00% | -100.0% |
| Q3 2013 | $713,000 | +4.5% | 76,961 | +10.6% | 0.00% | 0.0% |
| Q2 2013 | $682,000 | – | 69,560 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Abingworth LLP | 396,104 | $400,000 | 0.42% |
| Ancora Advisors LLC | 50,865 | $51,000 | 0.01% |
| EAGLE GLOBAL ADVISORS LLC | 145,710 | $146,000 | 0.00% |
| Acrospire Investment Management LLC | 5,200 | $5,000 | 0.00% |
| A.R.T. Advisors, LLC | 57,954 | $57,000 | 0.00% |
| Renaissance Technologies | 876,100 | $876,000 | 0.00% |
| PRELUDE CAPITAL MANAGEMENT, LLC | 4,600 | $5,000 | 0.00% |
| Cutler Group LLC / CA | 11,048 | $11,000 | 0.00% |
| PANAGORA ASSET MANAGEMENT INC | 133,846 | $134,000 | 0.00% |
| PRICE T ROWE ASSOCIATES INC /MD/ | 46,100 | $46,000 | 0.00% |